Overview

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2029-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if treatment with a siplizumab-based regimen can induce allogeneic tolerance in liver transplant recipients.
Phase:
PHASE2
Details
Lead Sponsor:
ITB-Med LLC
Treatments:
Adrenal Cortex Hormones
Cyclophosphamide
Mycophenolic Acid
siplizumab
Tacrolimus